Since most COVID-19 vaccines to date are based on the spike glycoprotein (protein S), our PepTivator Peptide Pools based on this protein are the perfect choice for re-stimulation of SARS-CoV-2–specific T cells after vaccination.
The example data highlight that stimulation with SARS-CoV-2 PepTivator Peptide Pools reveals the presence of virus-specific CD4+ T cells in a vaccinated donor. After vaccination, spike protein–reactive T cells were detected via stimulation with a mix of PepTivator SARS-CoV-2 Prot_S, Prot_S1, and Prot_S+ or with the single PepTivator SARS-CoV-2 Prot_S Complete. Both, the applied mix of peptide pools as well as SARS-CoV-2 Prot_S Complete alone cover the complete sequence of the mature spike protein and stimulate virus-reactive T cells to a similar extend.
Check out first publications using PepTivator Peptide Pools to investigate T cell responses after COVID-19 vaccination:
After stimulation with PepTivator Peptide Pools, SARS-CoV-2–reactive T cells can be detected and/or isolated for further research, for example:
PepTivator Peptide Pools mainly consist of 15-mer peptides with 11-amino-acid overlaps. They can bind to MHC class I as well as MHC class II complexes and thus are suitable for the antigen-specific stimulation of CD4+ and CD8+ T cells. Especially PepTivator Peptide Pools based on the spike protein are relevant for COVID-19 vaccination research:
PepTivator SARS-CoV-2 Prot_S covers predicted immunodominant sequence domains of the spike protein, PepTivator SARS-CoV-2 Prot_S1 spans the complete N-terminal S1 domain, and PepTivator SARS-CoV-2 Prot_S+ a part of the C-terminal S2 domain. Those products are the perfect choice for researchers interested in distinct parts of the spike protein but can also be combined to achieve a full-length coverage.
Newly available is our PepTivator SARS-CoV-2 Prot_S Complete: It covers the complete sequence of the mature spike protein (omitting the first four amino acids of the N-terminal signal peptide). For your convenience, PepTivator Prot_S Complete is optimized for water solubility and is delivered in one vial.
Find these PepTivator Peptide Pools based on the spike protein as well as kits for the analysis of SARS-CoV-2–reactive T cells listed under related products below.
If you are looking for solutions to stimulate, enrich, and analyze rare virus-specific T cells in COVID-19 research, we have your complete workflow covered! Find a detailed overview of innovative products, protocols, and webinars that support you at every step of your virus-specific T cell workflow here.
MACS Antigens for SARS-CoV-2 research enable the investigation of the virus-specific immune response, including antigen-specific B cells and antibodies. As most COVID-19 vaccines are based on the spike glycoprotein (protein S), our recombinant antigens, available for different parts of the spike protein, are perfectly suitable for studying the B cell response after vaccination.
The example data highlight that MACS Antigens enable the analysis of SARS-CoV-2–specific antibodies upon COVID-19 vaccination with a spike protein–based vaccine.
Spike protein–specific antibodies were detected in plasmapheresis samples of a vaccinated donor using Recombinant SARS-CoV-2 Spike-Prot (spike monomer) and Recombinant SARS-CoV-2 Spike RBD, whereas Recombinant SARS-CoV-2 Nucleoprotein and Recombinant Human ACE2 served as controls. Analysis of different plasma dilutions of a vaccinated or convalescent donor sample and comparison to the control sample (healthy donor plasma) illustrate the high sensitivity and specificity of MACS Antigens.
To identify spike protein–reactive B cells after COVID-19 vaccination, PBMCs were stained with Recombinant SARS-CoV-2 Spike-Prot (HEK)-Biotin tetramerized on streptavidin-PE and streptavidin-APC. The analysis illustrates that our recombinant spike protein is suited to detect spike protein–reactive B cells in convalescent as well as vaccinated donors.
Check out first publications using MACS Antigens to investigate B cell responses after COVID-19 vaccination:
MACS Antigens can, for example, be used for the following research applications:
Especially MACS Antigens based on the spike protein are relevant for COVID-19 vaccination research. We offer spike trimer and spike monomer as well as the receptor binding domain (RBD) and the S1 and S2 domains, all recombinantly expressed and available with or without biotin.
Find MACS Antigens based on the spike protein as well as kits for the analysis or enrichment of SARS-CoV-2–reactive B cells listed under related products below.
To complete your B cell research workflow, we offer solutions for B cell isolation, separation, culture, and characterization. Find a detailed overview of innovative products that support you at every step of your B cell research workflow here.
If you have further questions or need additional consultation about our products for SARS-CoV-2 research, please specify your queries in the contact form and we will come back to you: